Highland Private Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Highland Private Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,066	Closed	-$309K	–	166
2022 Q3	$309K	Buy	1,066 +56	+6%	+$16.1K	0.05%	126
2022 Q2	$285K	Buy	1,010 +2	+0.2%	+$535	0.04%	134
2022 Q1	$263K	Buy	1,008 +88	+10%	+$20.9K	0.04%	152
2021 Q4	$202K	Buy	+920	New	+$179K	0.03%	185
2020 Q4	–	Sell	-745	Closed	-$202K	–	145
2020 Q3	$202K	Buy	745 +17	+2%	+$4.69K	0.04%	128
2020 Q2	$211K	Buy	+728	New	+$197K	0.05%	126

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Highland Private Wealth Management's VRTX Position: Q4 2022 in Review

Highland Private Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 1,066 shares — an estimated $309K sold.

Highland Private Wealth Management first reported a position in VRTX in Q2 2020 and held it in 6 quarters. The position peaked at $309K in Q3 2022. 1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

Highland Private Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Highland Private Wealth Management sold 1,066 Vertex Pharmaceuticals shares in Q4 2022, an estimated $309K.
Highland Private Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 6 quarters.
Highland Private Wealth Management's Vertex Pharmaceuticals position peaked at $309K in Q3 2022.
1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Highland Private Wealth Management's 13F filing for Q4 2022.